Reducing Necrotizing Enterocolitis in Very Low Birth Weight Infants Using Quality Improvement Methods

Aloka L. Patel, MD1, Shamik Trivedi, MD2, Niyati P. Bhandari, MD1, Angela Ruf, APN3, Celina M. Scala, RD1, Gretchen Witowitch, RD1, Yimin Chen, RD1, Carrie Renschen, RNC-NIC, MSN1, Paula P. Meier, PhD1, and Jean M. Silvestri, MD1

1Rush University Medical Center, Chicago, IL, United States
2Washington University School of Medicine, St. Louis, MO, United States
3Children’s Hospital Colorado, Aurora, CO, United States

Abstract

Objective—Due to a rise in necrotizing enterocolitis (NEC, stage ≥2) among very low birth weight (VLBW, birth weight <1500g) infants from 4% in 2005-6 to 10% in 2007-8, we developed and implemented quality improvement (QI) initiatives. The objective was to evaluate the impact of QI initiatives on NEC incidence in VLBW infants.

Study Design—In September 2009 we developed a NEC QI multidisciplinary team that conducted literature reviews and reviewed practices from other institutions to develop a feeding protocol, which was implemented in December 2009. The team tracked intervention compliance and occurrence of NEC stage ≥2. In May 2010 we reviewed our nasogastric tube practice and relevant literature to develop a second intervention that reduced nasogastric tube indwelling time. The infants were divided into three groups: baseline (Jan 2008-Nov 2009, n219), QI phase 1 (Dec 2009-May 2010, n62), and QI phase 2 (June 2010-Nov 2011, n170).

Result—The NEC incidence did not decrease after implementation of the feeding protocol in QI phase 1 (19.4%), but did decline significantly after changing nasogastric tube management in QI phase 2 (2.9%). Multivariable logistic regression analysis demonstrated a significant relationship between QI phase and the incidence of NEC.

Conclusion—QI initiatives were effective in decreasing NEC incidence in our high human milk-feeding NICU. Nasogastric tube bacterial contamination may have contributed to our peak in NEC incidence.

Keywords

infant; preterm; enterocolitis; necrotizing; quality improvement; enteral nutrition

Conflict of interest

Drs. Patel and Meier have been funded by the NIH. The remaining authors declare no potential conflict of interest.
INTRODUCTION

Background Knowledge

Necrotizing enterocolitis (NEC) affects approximately 5-10% of very low birth weight (VLBW, birth weight <1500g) infants\(^1\)-\(^3\) and is associated with a mortality rate of 30%\(^4\). The mortality rate is even higher among VLBW infants who require surgical intervention for NEC, as is the incidence of short and long-term morbidities including short gut, growth failure and neurodevelopmental delay\(^5\)-\(^10\).

NEC is a multifactorial disease, representing the common end-point of multiple predisposing conditions\(^1\). Frequently associated risk factors that have been postulated in the pathogenesis of NEC include inappropriate colonization of the neonatal intestinal tract\(^11\)-\(^13\), an excessive inflammatory response by the immature intestinal epithelial cells\(^14\), anemia and transfusion related gut injury\(^15\)-\(^18\), prolonged exposure to antibiotics\(^19\),\(^20\) patent ductus arteriosus\(^21\),\(^22\) aggressive advancement of enteral feedings\(^17\), absence of enteral feedings\(^23\), non-human milk feedings\(^24\)-\(^26\), reduced gastric acid production\(^27\), and reduced gut motility\(^28\). Of these many factors, human milk has been shown to decrease the risk of necrotizing enterocolitis\(^24\),\(^29\),\(^30\), yet despite a very high rate of human milk feeding in VLBW infants at Rush University Medical Center (Rush) neonatal intensive care unit (NICU),\(^31\) the incidence of NEC stage ≥2 began to increase in 2007.

Local Problem

In June 2009, a sustained increase in the incidence of NEC stage ≥2 for 2007-8 (VLBW NEC incidence 9.2% in 2007 and 11.8% in 2008) was noted in comparison to previous years (VLBW NEC incidence 4.4% in 2005 and 4.1% in 2006). We retrospectively investigated potential risk factors for stage ≥2 NEC, focusing on feeding practices in our NICU including the transition from human milk to formula and/or addition of human milk fortifier (HMF).

We included 44 VLBW infants diagnosed with NEC (Bell’s criteria stage ≥2)\(^32\) from January 2005 through December 2008 and 44 randomly selected VLBW control infants, matched for birth year, gestational age, and birth weight. Infants were assigned to one of two groups based on birth year (2005-6 Low rate of NEC and 2007-8 High rate of NEC). During 2007-8 infants with NEC received HMF at an earlier postnatal age than controls (12.8 d NEC vs. 17.8 d control, \(p=0.04\)) and reached full feedings earlier than controls (15.7 d NEC vs. 19.8 d control, \(p=0.03\)). We considered these empirical findings in combination with the fact that we were not using a standardized feeding advancement protocol, and as a result the feeding practices in our NICU varied with individual health care providers. Additionally, we became aware that our feeding advancement practices for VLBW infants appeared somewhat more aggressive than at other US and Canadian centers (daily advancement by 20-30ml/kg/d without a minimal enteral nutrition or trophic feeding phase).

Intended Improvement

The data from that retrospective study were subsequently used as the basis for developing and implementing quality improvement (QI) initiatives in the Rush NICU, consisting of short-cycle improvement work and are still ongoing. We are reporting the outcomes for the
first 24 months after implementation of QI interventions, which consisted of two plan-do-study-act (PDSA) cycles.

METHODS

Ethical Issues

The sustained increase in rates of necrotizing enterocolitis in our unit was concerning to the medical team. To ensure our patients’ well-being, we needed to investigate potential sources and develop strategies to address them. In implementing the quality initiatives, privacy was maintained throughout the whole process. Any physical intervention was not out of the scope of an ordinary procedure utilized in a NICU.

Population/Setting

Rush University Medical Center NICU is an urban 57-bed tertiary care NICU in Chicago, IL that cares for approximately 130 VLBW infants annually. The demographic and clinical data reported here reflect VLBW infants born at Rush or admitted to the Rush NICU within the first week of life. We excluded from this report VLBW infants who were transferred to Rush after this time, had significant congenital anomalies, died within 14 days due to causes unrelated to stage 2 or 3 NEC, or were transferred out of Rush within 14 days after admission due to circumstances unrelated to NEC. Prior to implementation of quality initiatives, VLBW infants typically were started on enteral feedings at the attending neonatologist’s discretion and when maternal human milk was available with no minimal enteral nutrition phase. Feedings were advanced by 20-30ml/kg/day based on the infant’s stability. On average, powdered human milk fortifier (HMF) was introduced by DOL 13 and infants reached full enteral feeds by DOL 15. If supplementation was required, preterm formula was given since donor human milk was not routinely available in our NICU until 2013. Each feeding was prepared by the nurse at the infant’s bedside.

NEC stage 2 or 3 was defined as presence of at least 1 clinical sign (bilious gastric aspirate or emesis, abdominal distention, or blood in the stool) and radiographic findings of pneumatoisis intestinalis or portal venous gas.7,32 Cases of stage 3 NEC were verified by surgical pathology or radiographic findings of pneumatoisis or portal venous gas in addition to pneumoperitoneum. A diagnosis of spontaneous intestinal perforation (SIP) was determined based on early postnatal onset and pneumoperitoneum without associated pneumatoisis or portal venous gas.33 All cases of NEC and/or SIP were personally reviewed by a single neonatologist to verify the diagnosis using the above criteria. Unfortunately, no SIP data was available for the baseline cohort due to the retrospective nature of the data. Data from infants born after the quality initiatives were implemented were collected either prospectively for infants that were enrolled in a separate ongoing study during the years 2008-1234 or retrospectively through abstraction of the medical record for infants who were not enrolled in the ongoing study.

Planning the Interventions

Quality improvement phase 1—Based on these findings from the case-control study of 88 infants, we developed a NEC QI multidisciplinary team in September 2009 with the
intent of initiating PDSA cycles to address this problem. Our goal was to develop and implement QI initiatives to reduce the incidence of NEC in VLBW infants while monitoring infant growth and side effects of interventions (Table 1).\textsuperscript{35, 36} The team consisted of the neonatologist team leader, NICU medical director, two NICU dieticians, one advanced practice nurse (APN), NICU clinical nurse coordinator, and the director of NICU lactation services.

Literature searches were conducted to collect information in regards to HMF as well as the introduction and advancement of feedings in VLBW infants.\textsuperscript{37-51} Review of nutritional practices that were available from a range of other institutions across the US and Canada were conducted by team members. Using published research data and guidelines/protocols from other NICUs, a Rush VLBW infant feeding protocol was developed.\textsuperscript{37-39, 44, 45, 47-49, 51} Next, this protocol was presented to a larger multidisciplinary group consisting of all neonatologists, NICU APNs and several NICU nurses for review and comment. After revisions, the final feeding protocol (version 3) was disseminated to all NICU care providers, and implemented on December 1, 2009.

**Quality improvement phase 2**—We began to investigate other potential contributors to NEC such as human milk handling and NG tube care as a result of information presented at the 2010 Pediatric Academic Societies meeting.\textsuperscript{52} We also conducted another literature review,\textsuperscript{53-56} which revealed that gram negative bacterial colonization increased with duration of NG tube placement\textsuperscript{56} and that this gram negative colonization of feeding tubes was subsequently associated with NEC.\textsuperscript{53} Upon investigation of Rush NICU practices, we found that a new NG feeding tube system and accompanying tube maintenance practice changes had been introduced in November 2009. Specifically, the new system included additional extension tubing that was not being flushed consistently after feedings, leaving residual fluid in the lumen. Additionally, the manufacturer’s recommendation for NG tube integrity specified that the tubes could be maintained in place for up to 30 days. At this time, parental education about hygienic handling of human milk included a verbal description of pump cleaning methods.

Parental education about hygienic handling and cleaning of breast pumps was expanded to include a demonstration and provision of dishwashing soap and a basin for each mother. These changes were accompanied by a revision in the feeding protocol to emphasize feeding initiation with colostrum by DOL 2 due to concerns of gut atrophy and increased permeability with prolonged NPO status.\textsuperscript{57, 58} Rapid in-services were conducted for NICU nurses during May 2010 to institute the practice changes of 1) reducing NG tube indwelling time to a maximum of 7 days, identifying “Tube Tuesdays” as the weekly time to replace NG tubes, and 2) changing the extension tubing between each feeding. The NG tube handling changes, parental education reinforcement and increased emphasis on earlier feedings of colostrum were implemented by early June 2010. We continued to revise the feeding protocol (Figure 1) in order to achieve full enteral feedings sooner, thus decreasing the durations of TPN and central catheter use. Through increased dietician participation in daily rounds we aggressively adjusted feeding volumes to maintain growth targets.
Planning the Study of the Interventions

Process measures (compliance with feeding protocol rate of advancement for each BW group was categorized as compliant, faster than recommended rate of advancement, or slower than recommended rate of advancement), outcome measure (NEC), and balancing measures (TPN duration, postnatal growth velocity, postnatal growth restriction defined as birth weight ≥10\textsuperscript{th} percentile but discharge weight <10\textsuperscript{th} percentile, and culture-proven late onset sepsis unrelated to NEC were collected.

Analysis

Descriptive statistics included mean ± SD, median (IQR), and number (percent). Categorical data were analyzed using chi square or Fisher’s exact test, ordinal data were analyzed using the Kruskal-Wallis test, and continuous data were analyzed using analysis of variance (ANOVA). Post-hoc analyses were conducted using Tukey’s HSD. Factors significantly associated with NEC in bivariate analyses at p ≤1 were entered with QI phase (Baseline, QI phase 1 or QI phase 2) into a multivariable logistic regression model. Analyses were performed using SPSS 21.0 (Chicago, IL). Statistical significance was set at p<0.05. The monthly proportion of patients who developed NEC and surgical NEC was plotted on statistical process control charts using Microsoft Excel 2007 with Control Charts Add-in (Microsoft, Redmond, WA). These control charts were chosen because they permit tracking of changes in data over time and allow the differentiation between normal variation due to randomly occurring factors inherent to a process and variations that fall outside of expected variation of the process.

RESULTS

The baseline demographics and clinical outcomes for 451 VLBW infants are presented in Table 2. These infants are divided into the following groups: Baseline period (January 1, 2008-Nov. 30, 2009, 219 infants), QI phase 1 (Dec 1, 2009- May 31, 2010, 62 infants), and QI phase 2 (June 1, 2010- Nov 30, 2011, 170 infants). There were significant differences among the groups for gestational age, birth weight, race/ethnicity, small for gestational age at birth (SGA) status, and postnatal steroids.

Outcome measure

No decrease in NEC or surgical NEC was noted between the baseline period and after QI phase 1 (implementation of the feeding protocol), whereas a sharp decline in NEC incidence was noted after addition of the NG tube handling changes in QI phase 2 (Table 2 and Figure 2). The rate of surgical NEC cases progressively declined from 5% in the Baseline phase to 4.8% in QI phase 1 to 1.2% in QI phase 2. Multivariable logistic regression analysis controlling for potentially confounding factors associated with NEC in bivariate analyses (birth weight, sex, race/ethnicity, antenatal antibiotics) demonstrated a significant effect of QI phase on NEC (OR 0.46, 95%CI 0.31-0.68, p<.001). Other statistically significant factors that predicted NEC in the final model included male sex (OR 2.85, 95%CI 1.48-5.50, p=.002), birth weight (OR 0.999, 95%CI 0.998-1, p=.046) and receipt of antenatal antibiotics (OR 2.01, 95%CI 1.08-3.96, p=.028).
Process measures

Table 3 reports data about feeding initiation, advancement, fortification, type, and protocol compliance for the three groups of infants. Compliance with QI measures improved with time. Of noncompliant feeding practices, 52% of infants received feeding advancement at a faster rate than recommended in QI phase 1 and 21% in QI phase 2, 43% at a slower rate than recommended in QI phase 1 and 16% in QI phase 2.

Balancing measures

Balancing measures are reported in Table 4. During QI Phase 1, the standardization of the feeding protocol, especially slowing the advancement and fortification of feedings, had an adverse effect on postnatal growth, duration of TPN and the incidence of late onset sepsis. These balancing measures were addressed by progressively altering the feeding protocol to increase the feeding advancement rate during QI Phase 2. Additionally, the increase in the sepsis rate during QI Phase 1 led to increased attention on infection control policies for central catheter insertion and maintenance and to the formation of a second QI committee in the NICU. Subsequently, the rate of late onset sepsis decreased to below baseline values.

DISCUSSION

Through use of quality improvement methodologies, including PDSA cycles, we successfully targeted a NEC epidemic in our NICU. Whereas, our findings may not serve as the solution to NEC-related outbreaks in other institutions, the QI process by which we addressed this problem is generalizable to other centers when they evaluate their own practices that may potentially be related to NEC in their institutions. For example, previous findings have demonstrated the effectiveness of standardized feeding regimens in reducing NEC rates, and we anticipated that our QI phase 1 standardized feeding protocol would reduce the incidence of NEC in our NICU. However, when our NEC incidence did not decline between Baseline and QI phase 1, we searched for additional risk factors. We found that the new NG feeding tube system had been initiated approximately one month prior to the introduction of the standardized feeding protocol in QI phase 1, and likely confounded the impact of the standardized feeding protocol. This highlights the unintended consequences that can result from a seemingly unrelated decision that was felt to be cost effective and would decrease handling of infants, and the importance of multidisciplinary communication. Attention to the potential impact of the new NG tube change procedure on NEC rates occurred as a result of multiple unrelated situations: attendance at a PAS 2010 seminar, neonatologists’ bedside observations of residual fluid in NG extension tubing, and review of relevant literature. We quickly implemented quality initiatives which included more frequent NG tube changes and expanded parental education about hygienic handling and cleaning of breast pumps. By the end of QI phase 2, these combined changes resulted in a reduction in NEC rates. These processes illustrate the importance of multidisciplinary collaboration in QI processes in the NICU.

Experts have suggested that NEC incidence could be decreased by 50% by implementing a standardized feeding regimen and providing human milk to VLBW infants. Despite strong lactation support and human milk feeding rates over 90% in VLBW infants at our
institution, we had a NEC epidemic. Others have demonstrated similar epidemics, which led to investigations for a common infectious etiology and heightened infection control measures.\textsuperscript{67} Using multivariable regression models we attempted to control for the differences in patient population. While we could not adjust for all potential covariates, we did adjust for birth weight, gender, race/ethnicity, and antenatal antibiotics. Of note, the postnatal steroid rate in \textit{QI phase 1} was extremely high and reflected the institutional practice at the time to use postnatal steroids (primarily hydrocortisone) to facilitate extubation and/or prevent bronchopulmonary dysplasia. This had been a long-standing practice in our unit that existed even during the historically low NEC phase of 2005-6. The increased prevalence of postnatal steroid use during \textit{QI phase 1} likely reflected the lower gestational age and small N (62) of this group. While there is an association between postnatal steroid use and SIP,\textsuperscript{68} the cases of NEC were closely examined to distinguish NEC from SIP. Although one large network study has reported an association between postnatal steroid use and NEC,\textsuperscript{69} no causality was demonstrated. Additionally, a review of postnatal steroid practices across three large networks did not demonstrate any impact of steroid practices on incidence of NEC.\textsuperscript{70} Our results, while dramatic, may reflect targeted practices specific to our NICU that are not generalizable to other NICUs.

**CONCLUSIONS**

This quality improvement project led to a unified multidisciplinary approach for managing enteral feeding and monitoring postnatal growth in VLBW infants. Agreement and buy in evolved over a number of months after the feeding protocol was initiated. Although our initial approach was to advance feedings slowly, we found that we could progressively tailor the feeding protocol and improve growth while still achieving our primary outcome, reducing NEC rates. Even though growth velocities for VLBW infants did not change significantly over time, postnatal growth restriction improved and TPN days significantly decreased. These measures continue to be evaluated in our NICU as this is an ongoing process with additional PDSA cycles planned to continue to attempt to further lower our NEC rates.

**Acknowledgments**

**Funding source:** Partially funded by NIH Grant NR010009

**References**

1. Neu J, Walker WA. Necrotizing Enterocolitis. N Engl J Med. 2011; 364(3):255–264. [PubMed: 21247316]
2. Stoll B, Hansen N, Bell EF, Shankaran S, Laptook A, Walsh M, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010; 126(3): 443–456. [PubMed: 20732945]
3. Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA, et al. Mortality and Neonatal Morbidity Among Infants 501 to 1500 Grams From 2000 to 2009. Pediatrics. 2012; 129(6):1019–1026. [PubMed: 22614775]
4. Fitzgibbons SC, Ching Y, Yu D, Carpenter J, Kenny M, Weldon C, et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. J Pediatr Surg. 2009; 44(6):1072–1075. [PubMed: 19524719]
5. Clark RH, Gordon P, Walker WM, Laughon M, Smith PB, Spitzer AR. Characteristics of patients who die of necrotizing enterocolitis. J Perinatol. 2012; 32(3):199–204. [PubMed: 21593813]

6. Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing enterocolitis among neonates in the United States. J Perinatol. 2003; 23(4):278–285. [PubMed: 12774133]

7. Abdullah F, Zhang Y, Camp M, Mukherjee D, Gabre-Kidan A, Colombani PM, et al. Necrotizing enterocolitis in 20,822 infants: analysis of medical and surgical treatments. Clin Pediatr. 2010; 49(2):166–171.

8. Hintz SR, Kendrick DE, Stoll BJ, Vohr BR, Fanaroff AA, Donovan EF, et al. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics. 2005; 115(3):696–703. [PubMed: 15741374]

9. Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2007; 92(3):F193–F198. [PubMed: 16984980]

10. Shah DK, Doyle LW, Anderson PJ, Bear M, Daley AJ, Hunt RW, et al. Adverse neurodevelopment in preterm infants with postnatal sepsis or necrotizing enterocolitis is mediated by white matter abnormalities on magnetic resonance imaging at term. J Pediatr. 2008; 153(2):170–175. [PubMed: 18534228]

11. Wang Y, Hoenig JD, Malin KJ, Qamar S, Petrof EO, Sun J, et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. The ISME Journal. 2009; 3:944–954. [PubMed: 19369970]

12. de la Cochetiere MF, Piloquet H, des Robert C, Darmaun D, Galmiche JP, Roze JC. Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: the putative role of Clostridium. Pediatr Res. 2004; 56(3):366–370. [PubMed: 15201403]

13. Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, et al. Fecal Microbiota in Premature Infants Prior to Necrotizing Enterocolitis. Plos One. 2011; 6(6):e20647. [PubMed: 21674011]

14. Claud EC, Walker WA. Bacterial colonization, probiotics, and necrotizing enterocolitis. J Clin Gastroenterol. 2008; 42(Suppl 2):S46–S52. [PubMed: 18520617]

15. Christensen RD, Lambert DK, Henry E, Wiedmeier SE, Snow GL, Baer VL, et al. Is “transfusion-associated necrotizing enterocolitis” an authentic pathogenic entity? Transfusion. 2010; 50(5):1106–1112. [PubMed: 20051059]

16. Blau J, Calo JM, Dozor D, Sutton M, Alpan G, La Gamma EF. Transfusion-related acute gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. J Pediatr. 2011; 158(3):403–409. [PubMed: 21067771]

17. Lambert DK, Christensen RD, Baer VL, Henry E, Gordon PV, Besner GE, et al. Fulminant necrotizing enterocolitis in a multihospital healthcare system. J Perinatol. 2012; 32(3):194–198. [PubMed: 21566569]

18. Stritzke AI, Smyth J, Synnes A, Lee SK, Shah PS. Transfusion-associated necrotising enterocolitis in neonates. Arch Dis Child Fetal Neonatal Ed. 2013; 98(1):F10–F14. [PubMed: 22447991]

19. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sanchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009; 123(1):58–66. [PubMed: 19117861]

20. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic Exposure in the Newborn Intensive Care Unit and the Risk of Necrotizing Enterocolitis. J Pediatr. 2011; 159:392–397. [PubMed: 21489560]

21. Sankaran K, Puckett B, Lee DS, Seshia M, Boulton J, Qiu Z, et al. Variations in incidence of necrotizing enterocolitis in Canadian neonatal intensive care units. JPGN. 2004; 39(4):366–372. [PubMed: 15448426]

22. Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. JPGN. 2005; 40(2):184–188. [PubMed: 15699694]

23. Moss RL, Kalish LA, Duggan C, Johnston P, Brandt ML, Dunn JC, et al. Clinical parameters do not adequately predict outcome in necrotizing enterocolitis: a multi-institutional study. J Perinatol. 2008; 28(10):665–674. [PubMed: 18784730]
24. Meinzen-Derr J, Poindexter B, Wrage L, Morrow AL, Stoll B, Donovan EF. Role of human milk in extremely low birth weight infants’ risk of necrotizing enterocolitis or death. J Perinatol. 2009; 29(1):57–62. [PubMed: 18716628]

25. Sullivan S, Schanler RJ, Kim JH, Patel AL, Trawoeger R, Kiechl-Kohlendorfer U, et al. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. J Pediatr. 2010; 156(4):562–567. [PubMed: 20036378]

26. Cristofalo EA, Schanler RJ, Blanco CL, Sullivan S, Trawoeger R, Kiechl-Kohlendorfer U, et al. Randomized Trial of Exclusive Human Milk versus Preterm Formula Diets in Extremely Premature Infants. J Pediatr. 2013; 163(6):1592–1595. [PubMed: 23968744]

27. Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006 Feb; 117(2):e137–e142. [PubMed: 16390920]

28. Swanson JR. Necrotizing enterocolitis: is it time for zero tolerance? J Perinatol. 2013; 33:1–2. [PubMed: 23269229]

29. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O’Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol. 2007; 27:428–433. [PubMed: 17443195]

30. Johnson TJ, Patel AL, Bigger HR, Engstrom JL, Meier PP. Economic Benefits and Costs of Human Milk Feedings: A Strategy to Reduce the Risk of Prematurity-Related Morbidities in Very Low Birth Weight Infants. Adv Nutr. 2014; 5(2):207–212. [PubMed: 24618763]

31. Meier PP. Breastfeeding in the special care nursery. Prematures and infants with medical problems. Pediatr Clin North Am. 2001; 48(2):425–442. [PubMed: 11339162]

32. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986; 33(1):179–201. [PubMed: 3081865]

33. Rao SC, Basani L, Simmer K, Samnakay N, Deshpande G. Peritoneal drainage versus laparotomy as initial surgical treatment for perforated necrotizing enterocolitis or spontaneous intestinal perforation in preterm low birth weight infants. Cochrane Database Syst Rev. 2011; (6) Art. No.: CD006182.

34. Patel AL, Johnson TJ, Engstrom JL, Fogg LF, Jegier BJ, Bigger HR, Meier PP. Impact of early human milk on sepsis and health care costs in very low birthweight infants. J Perinatol. 2013; 33(7):514–519. [PubMed: 23370606]

35. Ellsbury DL, Ursprung R. A quality improvement approach to optimizing medication use in the neonatal intensive care unit. Clin Perinatol. 2012; 39(1):1–10. [PubMed: 22341532]

36. Langley, G.; Moen, R.; Nolan, K.; Nolan, T.; Norman, C.; Provost, L. The Improvement Guide: A Practical Approach to Enhancing Organizational Performance. 2. Jossey-Bass; San Francisco, California: 2009.

37. Tyson JE, Kennedy KA. Trophic feedings for parenterally fed infants. Cochrane Database Syst Rev. 2005; (3) CD000504.

38. Slagle TA, Gross SJ. Effect of early low-volume enteral substrate on subsequent feeding tolerance in very low birth weight infants. J Pediatr. 1988; 113(3):526–531. [PubMed: 3137320]

39. Dunn L, Hulman S, Weiner J, Kliegman R. Beneficial effects of early hypocaloric enteral feeding on neonatal gastrointestinal function: preliminary report of a randomized trial. J Pediatr. 1988; 112(4):622–629. [PubMed: 2895173]

40. Berson CL. Effect of early feeding on maturation of the preterm infant’s small intestine. J Pediatr. 1992; 120(6):947–953. [PubMed: 1593537]

41. Berson CL, Nordyke C. Enteral nutrients promote postnatal maturation of intestinal motor activity in preterm infants. Am J Physiol. 1993; 264(6 Pt 1):G1046–G1051. [PubMed: 8333531]

42. Berson CL, Bisquera JA, Paje VU. Prolonging small feeding volumes early in life decreases the incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2003; 111(3): 529–534. [PubMed: 12612332]

43. Troche B, Harvey-Wilkes K, Engle WD, Nielsen HC, Frantz ID 3rd, Mitchell ML, et al. Early minimal feedings promote growth in critically ill premature infants. Biol Neonate. 1995; 67(3): 172–181. [PubMed: 7640316]
44. Schanler RJ, Shulman RJ, Lau C, Smith EO, Heitkemper MM. Feeding strategies for premature infants: randomized trial of gastrointestinal priming and tube-feeding method. Pediatrics. 1999; 103(2):434–439. [PubMed: 9925837]

45. McClure RJ, Newell SJ. Randomised controlled study of clinical outcome following trophic feeding. Arch Dis Child Fetal Neonatal Ed. 2000; 82(1):F29–F33. [PubMed: 10634838]

46. Meetze WH, Valentine C, McGuigan JE, Conlon M, Sacks N, Neu J. Gastrointestinal priming prior to full enteral nutrition in very low birth weight infants. JPGN. 1992; 15(2):163–170. [PubMed: 1403464]

47. Premji SS, Chessell L, Paes B, Pinelli J, Jacobson K. A matched cohort study of feeding practice guidelines for infants weighing less than 1,500 g. Adv Neonatal Care. 2002; 2(1):27–36. [PubMed: 12903233]

48. Kamitsuka MD, Horton MK, Williams MA. The incidence of necrotizing enterocolitis after introducing standardized feeding schedules for infants between 1250 and 2500 grams and less than 35 weeks of gestation. Pediatrics. 2000; 105(2):379–384. [PubMed: 10654959]

49. Patole SK, de Klerk N. Impact of standardised feeding regimens on incidence of neonatal necrotising enterocolitis: a systematic review and meta-analysis of observational studies. Arch Dis Child Fetal Neonatal Ed. 2005; 90(2):F147–F151. [PubMed: 15724039]

50. Patole SK, Kadralraja R, Tuladhar R, Almonte R, Muller R, Whitehall JS. Benefits of a standardised feeding regimen during a clinical trial in preterm neonates. Int J Clin Pract. 2000; 54(7):429–431. [PubMed: 11070566]

51. Kuzma-O’Reilly B, Duenas ML, Greecher C, Kimberlin L, Muijsce D, Miller D, et al. Evaluation, development, and implementation of potentially better practices in neonatal intensive care nutrition. Pediatrics. 2003; 111(4 Pt 2):e461–e470. [PubMed: 12671166]

52. Kaufman DA. Strategies in Preventing Health Care Associated Infections: Getting a Balanced Microbiome for the Patient and Not the Lines and Tubes. PAS. 2010; 2120 abstract.

53. Mehall JR, Kite CA, Saltzman DA, Wallett T, Jackson RJ, Smith SD. Prospective study of the incidence and complications of bacterial contamination of enteral feeding in neonates. J Pediatr Surg. 2002; 37(8):1177–1182. [PubMed: 12149697]

54. Mehall JR, Kite CA, Gilliam CH, Jackson RJ, Smith SD. Enteral feeding tubes are a reservoir for nosocomial antibiotic-resistant pathogens. J Pediatr Surg. 2002; 37(7):1011–1012. [PubMed: 12077760]

55. Matlow A, Wray R, Goldman C, Streitenberger L, Freeman R, Kovach D. Microbial contamination of enteral feed administration sets in a pediatric institution. Am J Infect Control. 2003; 31(1):49–53. [PubMed: 12548258]

56. Hurrell E, Kucerova E, Loughlin M, Caubilla-Barron J, Hilton A, Armstrong R, et al. Neonatal enteral feeding tubes as loci for colonisation by members of the Enterobacteriaceae. BMC Infect Dis. 2009; 9:146. [PubMed: 19723318]

57. Siggers J, Sangild PT, Jensen TK, Siggers RH, Skovgaard K, Stoy AC, et al. Transition from parenteral to enteral nutrition induces immediate diet-dependent gut histological and immunological responses in preterm neonates. Am J Physiol Gastrointest Liver Physiol. 2011; 301(3):G435–G445. [PubMed: 21700903]

58. Shulman RJ, Schanler RJ, Lau C, Heitkemper M, Ou C, Smith EO. Early Feeding, Antenatal Glucocorticoids, and Human Milk Decrease Intestinal Permeability in Preterm Infants. Pediatr Res. 1998; 44:519–523. [PubMed: 9773840]

59. Patel AL, Engstrom JL, Meier PP, Kimura RE. Accuracy of methods for calculating postnatal growth velocity for extremely low birth weight infants. Pediatrics. 2005; 116(6):1466–1473. [PubMed: 16322172]

60. Patel AL, Engstrom JL, Meier PP, Jegier BJ, Kimura RE. Calculating postnatal growth velocity in very low birth weight (VLBW) premature infants. J Perinatol. 2009; 29(9):618–622. [PubMed: 19461590]

61. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001; 108(2):E35. [PubMed: 11483845]

J Perinatol. Author manuscript; available in PMC 2015 May 01.
62. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv Data. 2000; 314:1–27. [PubMed: 11183293]

63. Buttrey SE. An Excel Add-In for Statistical Process Control Charts. Journal of Statistical Software. 2009; 30(13):1–12. [PubMed: 21666874]

64. Plsek PE. Quality Improvement Methods in Clinical Medicine. Pediatrics. 1999; 103:203–214. [PubMed: 9917464]

65. Henderson G, Craig S, Brocklehurst P, McGuire W. Enteral feeding regimens and necrotising enterocolitis in preterm infants: a multicentre case-control study. Arch Dis Child Fetal Neonatal Ed. 2009; 94(2):F120–F123. [PubMed: 17768154]

66. Christensen RD, Gordon PV, Besner GE. Can we cut the incidence of necrotizing enterocolitis in half–today? Fetal Pediat Pathol. 2010; 29(4):185–198.

67. Wendelboe AM, Smelser C, Lucero CA, McDonald LC. Cluster of necrotizing enterocolitis in a neonatal intensive care unit: New Mexico, 2007. Am J Infect Control. 2010; 38(2):144–148. [PubMed: 19822381]

68. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004; 114(6):1649–1657. [PubMed: 15574629]

69. Yee WH, Soraisham AS, Shah VS, Aziz K, Yoon W, Lee SK, et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. Pediatrics. 2012; 129(2):e298–e304. [PubMed: 22271701]

70. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the Use of Postnatal Steroids for Bronchopulmonary Dysplasia in 3 Large Neonatal Networks. Pediatrics. 2006; 118:e1328–e1335. [PubMed: 17079534]

J Perinatol. Author manuscript; available in PMC 2015 May 01.
### A. Initial Feeding protocol for infants with birth weight 400-1800 grams (version 1)

| BIRTH WEIGHT | TROPHIC FEEDING | DAILY ADVANCEMENT | GOAL FEEDING AMOUNT at 140ml/kg/d | Days from feeds initiation to 140ml/kg/d | FORTIFICATION | FORMULA |
|--------------|-----------------|-------------------|-----------------------------------|------------------------------------------|---------------|---------|
| 400-750g     | 1ml q4hr x 4 days | Day 5 of feedings: 1ml q2hr for 36 hr, THEN advance by 1ml q36hr (will increase amount by 1 ml/feed every 18 feedings) | 6-9ml q2 | 12-16 | ![Arrow](#) | ![Arrow](#) |
| 751-1000g    | 1ml q2hr x 4 days | Day 5 of feedings: advance by 1ml/feed once q24hr | 9-12ml q2 | 12-15 | ![Arrow](#) | ![Arrow](#) |
| 1001-1250g   | 1ml q2hr x 3 days | Day 4 of feedings: advance daily by 16ml/kg/day | 12-15ml q2 | 12 | ![Arrow](#) | ![Arrow](#) |
| 1251-1500g   | 3ml q3hr x 3 days | Day 4 of feedings: advance daily by 15ml/kg/day | 22-26ml q3 | 12 | ![Arrow](#) | ![Arrow](#) |
| 1501-1800g   | Start at 20 ml/kg/d | Advance daily by 20 ml/kg/d | 26-32ml q3 | 8 | ![Arrow](#) | ![Arrow](#) |

1. If at least 12 days old and feedings at 140ml/kg/day then Fortify - 1 packet: 50ml human milk. 20 calorie formula until at full feedings (140ml/kg/day). Then switch to 24 calorie/oz Formula.

### B. Final Feeding protocol for infants with birth weight 400-1500 grams (version 8)

| BIRTH WEIGHT | TROPHIC FEEDING | DAILY ADVANCEMENT | GOAL FEEDING AMOUNT at 140ml/kg/d | Days from feeds initiation to 140ml/kg/d |
|--------------|-----------------|-------------------|-----------------------------------|------------------------------------------|
| 400-750g     | 1ml q4hr x 5 days | Day 6 of feedings: 1ml q2hr for 24 hr, THEN advance by 1 ml/feed once q24hr | 6-9ml q2 | 11-14 |
| 751-1000g    | 1ml q2hr x 4 days | Day 5 of feedings: advance by 2ml/feed once q24hr | 9-12ml q2 | 9-11 |
| Weight Range | Feeding Protocol | Day 4 of feedings: advance daily by | q2 | q3 |
|--------------|-----------------|-----------------------------------|----|----|
| 1001-1250g   | 1ml q2hr x 3 days | 20ml/kg/day                       | 12-15ml | 10 |
| 1251-1500g   | 3ml q3hr x 3 days | 20ml/kg/day                       | 22-26ml | 9  |

**FORTIFICATION**

If at least 11 days old and feedings at 140ml/kg/day then Fortify - 1 packet:50ml human milk.

THEN, if stable on the next day - Fortify 1 packet:25ml human milk.

**FORMULA**

Start with 20 calorie formula until at full feedings (140ml/kg/day).

THEN, if stable next day, change to 24 calorie/oz Formula.

---

*Figure 1.*

Initial (version 1) and Final feeding protocols (version 8) used for feeding advancement in VLBW infants
Figure 2.
Control chart (p-chart) presenting the proportion of VLBW infants that developed NEC stage 2 or 3 (A) and surgical NEC (B). Major QI initiatives were implemented in December 2009 and June 2010 as delineated by the dotted lines. The solid black lines represent the monthly observed proportion of VLBW infants that developed NEC stage 2 or 3 (A) and surgical NEC (B). The solid grey lines represent the center line or the mean proportion of infants that developed NEC stage 2 or 3 or surgical NEC for each phase. The dashed grey lines represent the upper control limits (UCL), corresponding to 3SD from the mean. The lower control limits are at 0. A downward trend (6 consecutive data points below center line) in NEC (A) and a significant shift (8 consecutive points below the center line) in surgical NEC (B) were observed in QI phase 2; however, a special cause variation (above
the UCL) was noted in October 2011 for surgical NEC. Tests were performed with unequal sample sizes.

NEC, necrotizing enterocolitis; QI, Quality improvement; UCL, upper confidence limit.
Figure 3.
The incidence of NEC stage 2 or 3 and surgical NEC in VLBW infants from January 2005 - December 2011. The solid black line represents the observed percentage of VLBW infants that developed NEC stage 2 or 3. The dashed black line represents the observed percentage of VLBW infants that developed surgical NEC. NEC, necrotizing enterocolitis; VLBW, very low birth weight.
| DATE         | ACTION                                                                 |
|--------------|-------------------------------------------------------------------------|
| **Baseline Data Acquisition and Team Development** |                                                                          |
| 6/2009 – 8/2009 | Conducted case control review of NEC cases and identified risk factors: |
|               | Rapid introduction of fortifier                                          |
|               | Variable feeding regimens                                               |
|               | Overall rates of feeding advancement faster than other centers           |
| **Quality improvement phase 1 (9 months)** |                                                                          |
| 9/01/2009     | Established multidisciplinary NEC QI team                               |
|               | Reviewed retrospective study findings                                    |
|               | Reviewed literature                                                     |
|               | Developed feeding protocols for very low birth weight infants (versions 1, 2 & 3) |
|               | Completed data collection for baseline period (Jan-Nov 2009 infants not included in case-control study) |
| 12/01/2009    | Implemented feeding protocol version 3                                  |
| 1/21/2010     | No substantial changes - updated feeding protocol version 4 to improve clarity |
| 5/11/2010     | NEC rate remained elevated - Evaluate other processes:                  |
|               | Human milk handling, NG tubes, timing of feeding initiation              |
| **Quality improvement phase 2 (18 months)**  |                                                                          |
| 5/25/2010     | Discontinued practice of prolonged NG tube dwell duration by implementing:|
|               | Change NG tubes every Tuesday.                                           |
|               | Change extension tubing between each feeding                           |
|               | Reeducation for breast pump handling and cleaning                       |
| 6/08/2010     | Prioritized initiation of colostrum trophic feedings at Day 2 (feeding protocol version 5) |
| 7/13/2010     | Focus on growth and TPN duration: shortened feeding protocol (version 6)|
|               | Birth weight <1000g: Advance feedings faster after reach 100ml/kg/d     |
|               | Birth weight >1000g: Advance faster than prior protocol version          |
| 12/07/2010    | Focus on growth and TPN duration, noted improvement in NEC rates:       |
|               | Shortened feeding protocol (version 7)                                  |
|               | Birth weight <1000g: Advance feedings faster                            |
|               | Birth weight >1000g: no changes                                         |
| 10/04/2011    | Focus on protein intake: changed feeding protocol (version 8)           |
|               | Shorten interval between partial to full fortification of human milk (22kcal/oz to 24kcal/oz) |

NEC, necrotizing enterocolitis; NG, nasogastric; QI, quality improvement; TPN, total parenteral nutrition
### Table 2

Sample Characteristics

|                      | Baseline Jan 1, 2008 - Nov. 30, 2009 (n 219) | QI phase 1 Dec 1, 2009 - May 31, 2010 (n 62) | QI phase 2 June 1, 2010 - Nov 30, 2011 (n 170) |
|----------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Gestational age (wk) | 28.1±2.5b                                   | 27.2±2.1a, c                                | 28.4±2.8b                                   |
| Birth weight (g)     | 1070±270b                                   | 972±267a                                   | 1053±272                                    |
| Male gender**        | 109 (49%)                                   | 34 (55%)                                   | 84 (49%)                                    |
| Maternal race / ethnicity** |                                    |                                             |                                             |
| African American     | 104 (48%)f                                  | 28 (45%)                                   | 92 (54%)a                                   |
| Hispanic             | 65 (30%)                                    | 15 (24%)                                   | 30 (18%)                                    |
| Non-Hispanic Caucasian | 44 (20%)                                  | 17 (27%)                                   | 35 (21%)                                    |
| Other                | 6 (2%)                                      | 2 (3%)                                     | 13 (8%)                                     |
| SGA at birth**       | 41 (19%)f                                   | 8 (13%)c                                   | 56 (33%)a,b                                 |
| Antenatal steroids (complete course)** |                          | 156 (72%)                                  | 49 (86%)                                    |
| Antenatal antibiotics** | 116 (54%)                                  | 35 (67%)                                   | 91 (54%)                                    |
| Multiple gestation** | 47 (22%)                                    | 16 (26%)                                   | 44 (26%)                                    |
| Inborn**             | 188 (86%)                                   | 48 (77%)                                   | 152 (89%)                                   |
| C-section delivery** | 151 (69%)                                   | 39 (63%)                                   | 118 (69%)                                   |
| Apgar 5 min ***      | 8 (7-9) n 215                               | 8 (6.75-9) n 62                            | 8 (7.9) n 170                               |
| Postnatal steroid**  | 61 (28%)b                                   | 29 (47%)a,c                                | 45 (27%)b                                   |
| PDA**                | 92 (42%)                                    | 35 (57%)                                   | 81 (48%)                                    |
| SIP**                | NA                                          | 4 (7%)                                     | 8 (5%)                                      |
| NEC stage 2 or 3**   | 35 (16%)f                                   | 12 (19%)c                                  | 5 (3%)a,b                                   |
| Surgical NEC**       | 11 (5%)                                     | 3 (5%)                                     | 2 (1%)                                      |

* Mean ± SD;  
** n (%);  
*** Median (IQR);  
PDA, patent ductus arteriosus; QI, Quality improvement; SGA, small for gestational age; SIP, spontaneous intestinal perforation; NEC, necrotizing enterocolitis.

<sup>a</sup> p<0.05 compared to Baseline.

*P* J Perinatol. Author manuscript; available in PMC 2015 May 01.
b $p<0.05$ compared to QI phase 1.
c $p<0.05$ compared to QI phase 2.
Table 3

Process Measures

|                              | Baseline Jan 1, 2008 - Nov 30, 2009 (n 219) | QI phase 1 Dec 1, 2009 - May 31, 2010 (n 62) | QI phase 2 June 1, 2010 - Nov 30, 2011 (n 170) |
|------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| DOL feeding initiation (d) * | 4 (3-7) n 210                                 | 5.5 (4-9)\(^{bc}\) n 62                      | 4 (2-5)\(^{b}\) n 169                         |
| Fed by DOL 3 **              | 93 (43%)\(^{b}\)                              | 12 (19%)\(^{abc}\)                           | 84 (49%)\(^{b}\)                              |
| DOL fortifier started (d) *  | 13 (8.75-18)\(^{bc}\) n 58                    | 29 (18-38.5)\(^{abc}\) n 61                  | 18 (14-25)\(^{abc}\) n 166                    |
| DOL formula introduced (d) * | 11 (3-18)\(^{b}\) n 43                        | 18.5 (12.25-37.5)\(^{a}\) n 48                | 16 (7.5-22.5) n 117                           |
| DOL full feedings (d) *      | 15 (11-22)\(^{b}\) n 206                      | 25.5 (17-37)\(^{abc}\) n 62                  | 17 (13-23)\(^{b}\) n 168                      |
| Interval start feedings-fortifier (d) * | 7.5 (5-11.25)\(^{bc}\) n 58 | 20 (13-32)\(^{abc}\) n 61 | 12.5 (10-18.25)\(^{abc}\) n 166 |
| Interval start-full feedings (d) * | 9.5 (7-15)\(^{b}\) n 206                      | 18.5 (12-31)\(^{abc}\) n 62                  | 11 (9-17)\(^{b}\) n 168                       |
| Human milk – any **          | 201 (99%)\(^{e}\) n 202                       | 60 (97%)\(^{e}\) n 62                        | 157 (92%)\(^{d}\) n 170                       |
| Compliance with feed advancement ** | NA                                  | 36 (58%)\(^{c}\)                           | 133 (78%)\(^{b}\)                             |
| Compliance with fortification ** | NA                                  | 49 (80%)                                  | 121 (75%)                                  |

* Median (IQR);
** n (%);
DOL, day of life; IQR, interquartile range; QI, Quality improvement.

\(^{a}\) p<0.05 compared to Baseline.

\(^{b}\) p<0.05 compared to QI phase 1.

\(^{c}\) p<0.05 compared to QI phase 2.

J Perinatol. Author manuscript; available in PMC 2015 May 01.
Table 4

Balancing Measures

| Measure                              | Baseline Jan 1, 2008 - Nov. 30, 2009 (n 219) | QI phase 1 Dec 1, 2009 - May 31, 2010 (n 62) | QI phase 2 June 1, 2010 - Nov 30, 2011 (n 170) |
|--------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Discharge PMA (wk) *                 | 38.3 ± 4.5                                  | 39.4 ± 3.7                                  | 38.9 ± 4.3                                  |
| Discharge weight (g) *               | 2539 ± 817                                  | 2692 ± 639                                  | 2564 ± 820                                  |
| Length of NICU stay (d) ***          | 61 (42-84) b                                | 79 (53.75-110.25) a                         | 63.5 (44.5-93)                              |
| Growth velocity from birth to discharge (g/kg/d) *** | 12.7 (11.3-14.1)                           | 12.7 (11.7-13.5)                            | 12.8 (11.0-14.0)                            |
| Below 10th percentile at discharge **| 87 (40%)                                    | 27 (44%)                                    | 86 (51%)                                    |
| Postnatal growth restriction **      | 50 (23%)                                    | 19 (31%)                                    | 40 (24%)                                    |
| TPN (d) ***                          | 14 (9-22.25) b n 146                        | 19 (13-33) a c n 61                         | 14 (11-20.5) b n 149                       |
| Late onset sepsis (unrelated to NEC)** | 24 (11%)                                    | 15 (24%) c                                 | 15 (9%) b                                   |
| Death **                             | 8 (4%)                                      | 0 (0%)                                      | 1 (1%)                                      |

* Mean ± SD;  
** n (%);  
*** Median (IQR);  

IQR, interquartile range; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; PMA, postmenstrual age; QI, Quality improvement; TPN, total parenteral nutrition.

* p<0.05 compared to Baseline.  
b p<0.05 compared to QI phase 1.  
c p<0.05 compared to QI phase 2.